AbbVie, Bristol-Myers to combine checkpoint inhibitors, Rova-T in cancer trials

FDA panel backs Amgen’s Humira copy, but don’t expect to see it anytime soon

Insys to take on AbbVie with FDA approval for oral cannabinoid

GSK, Pfizer, AbbVie back next-gen integrin drugs in $52M Series A

AbbVie scraps Infinity collab in wake of weak data; biotech slashes jobs

UPDATED: AbbVie's $10B cancer drug Rova-T panned at ASCO

FDA approves AbbVie/Biogen’s monthly MS jab, but with safety warnings

EuroBiotech Report: AbbVie adds $250M to Galapagos cystic fibrosis deal

AbbVie, Biogen gain CHMP nod for new MS drug Zinbryta

AbbVie bags a unicorn with $9.8B buyout deal for Stemcentrx